usceptibilities to retroviral infections differ within a single host species as exemplified by the presence of slow or rapid progressors and elite controllers among individuals infected with human immunodeficiency virus (1). Friend virus (FV) infection of adult immunocompetent mice is useful to study the genetic, molecular, and cellular bases of resistance against retroviruses (2, 3). FV consists of replication-competent Friend murine leukemia virus (FMuLV) and defective spleen focus-forming virus (SFFV). In C57BL/6 (B6) mice homozygously possessing the resistant Fv2 allele (4), not only is SFFV-induced proliferation of infected erythroid progenitor cells limited, but they are also actively eliminated by cellular immune responses (5). CD4 ϩ T cells are required for SFFV elimination, while B-lymphocytes are required for F-MuLV elimination (5, 6). FV-susceptible (BALB/c ϫ B6)F 1 (CB6F 1 ) mice rapidly develop splenomegaly and succumb to leukemia within 2 months postinfection (pi), but they can be protected against FV by a single immunization with an F-MuLV-encoded CD4 ϩ T cell epitope, Env 462-479 (7). This vaccine-induced protection also requires B-lymphocytes, while FV-infected cells are eliminated in the absence of CD8 ϩ T cells (8). For the production of FV-neutralizing antibodies (Ab), CD11c ϩ dendritic cells and Myd88 that transduces signals from Toll-like receptors (TLR) are crucial (9). TLR7 senses retroviral entry (10) and inhibits virus replication over the first 5 days of infection through rapid production of nonneutralizing IgM (11). TLR7-deficient mice failed to generate germinal centers and IgM-negative (IgM Ϫ ) B cells upon FV infection (12), suggesting that immunoglobulin somatic hypermutation (SHM) and class switch recombination (CSR) are associated with neutralizing Ab production and FV control. To examine directly if SHM and CSR are required for FV neutralization, we utilized mice deficient in activation-induced cytidine deaminase (AID), a B cell-specific enzyme required for SHM and CSR (13).
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AID-deficient (AID Ϫ/Ϫ ) B6 and BALB/c mice were purchased from Riken BioResource Center, Tsukuba, Japan, and bred and maintained along with B cell-deficient MT/MT mice (5 (Fig. 1B) . Thus, AID-mediated SHM and CSR are not required for F-MuLV elimination. Plasma viremia and virus-neutralizing Ab were detected as described previously (14) . While MT/MT mice remained viremic even at 16 weeks pi, AID Ϫ/Ϫ mice cleared viremia, albeit less quickly than the WT mice did (Fig. 1D) . As virus particles in the plasma might not be detected by the above-described focus-formation assays in the presence of antiviral Ab, viral RNA was extracted from 20 l of each plasma sample using an RNeasy Plus kit (Qiagen, Valencia, CA) and eluted into 40 l of RNase-free water, and 11 l of each eluate was used for cDNA synthesis using the oligo(dT) 20 primer and a SuperScript III first-strand synthesis system (Life Technologies, Carlsbad, CA). Real-time PCR assays for the quantification of the F-MuLV genome were performed as described previously (5) . At 4 weeks pi, the level of the F-MuLV genome was below the limit of detection in 4 of the 5 infected WT mice, while low levels of the F-MuLV genome were detectable in the plasma samples from infected AID Ϫ/Ϫ mice ( Fig. 1D , right panel). However, the average plasma number of F-MuLV genome was significantly (14) . Each closed circle represents the actual value obtained from an individual mouse. The dashed line indicates the limit of detection at 200 focus-forming units (FFU)/ml. One-way analysis of variance (ANOVA) and Tukey's post hoc tests were performed for multiple comparisons (*, P Ͻ 0.01; **, P Ͻ 0.001). (Right panel) DNA-free viral RNA was extracted from plasma samples and cDNA synthesized. The cDNAs (5 l each) generated as described above were mixed with 20 l of a master mixture containing 2ϫ Platinum Quantitative PCR SuperMix-UDG with ROX (Life Technologies), 5 pmol of F-MuLVspecific primers (5), and 2.5 pmol of the TaqMan probe. Standard curves obtained by using a plasmid containing the F-MuLV env gene as a template were linear over the range of 10 to 10 6 copies. With an equivalent of 1.375 l plasma per reaction mixture, the limit of detection in this assay was 7,272 copies per ml plasma (dashed line). Each closed circle represents the actual value obtained from an individual mouse. **, P Ͻ 0.0001 Ͻ ␣ 3 (0.05) ϭ 0.017 (by Student's t test performed with Bonferroni's correction for multiple comparisons). (E) Changes in serum F-MuLV-neutralizing titers of either the IgM class or IgG class in AID Ϫ/Ϫ (n ϭ 6) or WT (n ϭ 5) mice after FV inoculation. Mice were bled and neutralizing titers were determined as described previously (8, 14) . Each data point shows the mean Ϯ the standard error of the mean (SEM) calculated with values obtained from the five or six mice described above. For panels A, B, D, and E, similar results were obtained in two separate experiments. lower in infected AID Ϫ/Ϫ than in the MT/MT mice and was not different from the number seen in the WT mice. Thus, AID Ϫ/Ϫ B6 mice can control viremia. AID Ϫ/Ϫ mice possessed high titers of virus-neutralizing Ab at 3 weeks pi (Fig. 1E) , clearly indicating that IgM produced in the absence of AID can neutralize F-MuLV. We next examined if SHM and CSR are required for vaccine- mice, 5 CFA and 9 peptide i. Statistically significant differences between the peptide-immunized and unimmunized groups were detected by the Mantel-Cox test (*, P Ͻ 0.005; **, P Ͻ 0.0005; ***, P Ͻ 0.0001). †, significant differences in survival between the immunized AID Ϫ/Ϫ and immunized WT mice by the Mantel-Cox test (P Ͻ 0.05).
induced protection of FV-susceptible mice. As previously described (7, 8) , WT CB6F 1 mice were 100% protected by a single peptide immunization, while MT/MT mice died regardless of the presence or absence of vaccination. About half of the vaccinated AID Ϫ/Ϫ mice were free from polycythemia and survived past 12 weeks pi ( Fig. 2A and B) , indicating that SHM and CSR may contribute to but are not absolutely required for peptideinduced protection of CB6F 1 mice against FV. To confirm that AID Ϫ/Ϫ mice can control FV after peptide immunization, we reduced the challenge dose to 10 SFFU, which still killed most of the unimmunized CB6F 1 mice by 12 weeks pi (Fig. 2C) . While no effect of peptide immunization was observed in MT/MT mice, 90% of AID Ϫ/Ϫ mice were protected against the low-dose challenge. Levels of viremia determined by both fluorescence focus assays and the enumeration of F-MuLV genomic RNAs and numbers of FV infectious centers were all significantly lower in peptide-immunized than in unimmunized animals even in the absence of AID (Fig. 3A and B) , and virus-neutralizing IgM became detectable in immunized AID Ϫ/Ϫ mice as quickly as in the WT mice (Fig. 3C) .
To examine directly if IgM produced in the absence of AID can contribute to FV control, passive transfer was attempted. AID Ϫ/Ϫ CB6F 1 mice were subjected to peptide immunization and challenged with FV, and sera were collected at 3 weeks pi and subjected to heat inactivation (14) . To reproduce Ab production in infected mice, we examined the kinetics of anti-FV Ab production. F-MuLV particles were purified (15) and adsorbed onto a nitrocellulose membrane (Multiscreen-HA; Millipore, Bedford, MA). A serially diluted spleen cell suspension was added to the membrane-bottomed wells and incubated for 18 h, followed by Ab detection with horseradish peroxidase-conjugated anti-mouse IgM (SouthernBiotech, Birmingham, AL) and 3-amino-9-ethylcarbazole. In peptide-immunized AID Ϫ/Ϫ mice, cells producing anti-F-MuLV IgM were detected at 3 days pi, and the cell numbers became significantly higher than those in unimmunized mice at 7 days pi (Fig. 4A) . F-MuLV-neutralizing serum Ab started to be detected in peptide-immunized AID Ϫ/Ϫ mice at 6 days pi with an average titer of 2 2.5 (n ϭ 5). Therefore, we started injecting B cell-deficient CB6F 1 mice with the pooled sera on day 5 pi (Fig.  4B ). Prior to serum transfer, recipients were either immunized with the peptide or given adjuvant alone and challenged with 150 SFFU FV 3 weeks later. Peptide-immunized MT/MT recipient mice given immune sera from the WT mice possessed undetectable or very low levels of FV infectious centers and normal spleen sizes at 4 weeks pi, indicating the efficacy of the adoptive immunization described above (data not shown). Immunized mice given naive sera all died by 7 weeks pi, while a significantly higher proportion of those given the immune sera from AID Ϫ/Ϫ mice survived past 12 weeks pi (Fig. 4B) , reproducing the partial protection of immunized AID Ϫ/Ϫ mice (Fig. 2B) . A previous report ). (C) Serum titers of virus-neutralizing IgM or IgG were measured at the indicated time points for a period of 4 weeks after FV inoculation as described previously (8, 14) . Each data point shows the mean Ϯ SEM calculated with data from five to six mice per group. demonstrated the requirement of host T cells for passive immunotherapy with FV-neutralizing monoclonal IgG (16) . Similarly, no protection was observed when the recipients were not previously immunized. Serum transfer on day 14 pi alone was ineffective.
As a recent report (17) has indicated that an apolipoprotein B mRNA editing enzyme, catalytic polypeptide 3 ([APOBEC3]), expressed in B6 mice can complement AID in generating SHM and as we performed the present study in the presence of B6-derived APOBEC3, the IgM Ab we detected in AID Ϫ/Ϫ mice might not necessarily have been unmutated, although whether APOBEC3 alone induces significant SHM in the absence of AID has not been examined. Nevertheless, it is now clear that, although TLR7-Myd88 signaling is required for anti-FV Ab production and germinal center responses (9-12), AID-mediated SHM and CSR are not absolutely required, and IgM produced in the absence of AID can still contribute to spontaneous and vaccine-induced resistance to FV infection.
